Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  01:09 2022-11-28 pm EST
9.995 USD   -6.41%
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-09-2022 09:50 AM
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

ALX Oncology Announces Upcoming Investor Conference Participation

09/01/2022 | 07:01am EST

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences.

Citi's 17th Annual BioPharma Conference
Format: Investor meetings
Date: Wednesday, September 7
Location: Boston, MA

H.C. Wainwright 24th Annual Global Investment Conference
Format: Fireside chat with analyst, Swayampakula Ramakanth
Date: Monday, September 12
Time: 7:00 AM Eastern Time
Location: Virtual
Webcast link: Available here

A live webcast of the H.C. Wainwright fireside chat is available here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

Investor Contact:

Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com

Argot Partners
(212) 600-1902
alxoncology@argotpartners.com

Media Contact:

Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com


All news about ALX ONCOLOGY HOLDINGS INC.
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual..
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains B..
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
GL
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
11/08ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/03ALX Oncology to Present New Clinical Data on Evorpacept ináAcute Myeloid Leukemia at 64..
GL
11/02ALX Oncology Announces Upcoming Investor Conference Participation
GL
10/31ALX Oncology Secures $100 Million Loan Facility Deal
MT
10/31Alx Oncology Holdings Inc : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -131 M - -
Net cash 2022 255 M - -
P/E ratio 2022 -3,36x
Yield 2022 -
Capitalization 435 M 435 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 55
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 10,68 $
Average target price 35,00 $
Spread / Average Target 228%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. GarcÝa Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-50.30%435
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.58%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930